Posts Tagged ‘clinical research jobs uk’

CK Clinical Salary Survey

Friday, February 15th, 2013

Your chance to complete the 2013 CK Clinical Salary Survey is almost over.

Pharmceutical jobsThe clinical salary survey will be closing at the end of February so this is the last chance you will have to  take part. It takes just 5 minutes to complete, and your participation will help us understand what the cialis online 2012 clinical salary brackets were. The results of this survey will be published and will help you with your job and salary expectations for 2013.

Click on the link below to complete the CK Clinical Salary Survey

https://www.surveymonkey.com/s/ckclinicalsalarysurvey

Are you are currently looking for a job within the Clinical

industry?

Click here to view all our clinical jobs

Pharmaceutical jobs    

 

Document Review and Maintenance Manager – Berkshire/Europe

Monday, January 7th, 2013

Shreeya Patel at CK Clinical is recruiting a Document Review and Maintenance Manager to join a global CRO on a permanent basis. This role is available in a number of locations across the UK.

As a Document Review and Maintenance Manager you will be part of an enthusiastic global service group involved in the delivery of the Global Site Services (GSS) component of assigned

studies globally. This position provides an excellent opportunity to be involved in a fast paced department currently experiencing incredible growth.

Responsibilities

  • Lead the cross-unit coordination of both internal and external, inclusive of sub-contractors, teams involved in the following areas:-
  • Document review aspects of Global Site Services deliverables including overall accountability and delivery to time and quality.
  • Document collection activities of the Global Site Services (GSS) component of assigned projects during maintenance and close-out including overall accountability and delivery to time, cost and quality

Qualifications

  • Masters or University/college degree (life science preferred), or certification in a related allied health profession (i.e. nursing, medical or laboratory technology) from an appropriately accredited institution.
  • Broad knowledge of drug development process and client needs.
  • PMP certification.
  • Minimum of five years of relevant clinical research/regulatory experience in a pharmaceutical company/CRO including a strong working knowledge of the ICH guidelines, demonstrated skills and experience with review and maintenance of investigator package/essential documentation and demonstrated line management experience.
  • A working knowledge of ICH GCP, US FDA regulations, regulations applicable to local office, guidelines, and practices regarding Good Clinical Practices.
  • Ability to network, negotiate and liaise face to face and remotely with high level internal and external stakeholders in a professional manner
  • Good computer skills with good working knowledge of a range of computer programs.
  • Ability to present to staff at all levels.
  • Detailed knowledge of financial control procedures (i.e. costing systems, time reporting).
  • Ability to resolve project-related problems and priorities workload for self and team.
  • Ex

    flagyl online'>buy flagyl

    online

    perience in managing projects in a virtual environment.

  • Working knowledge of project management processes, especially concerning site maintenance and document review.
  • Demonstrated ability to handle multiple competing priorities and to utilize resources effectively.
  • Financial awareness and ability to actively utilize financial tracking systems.
  • Working knowledge of time and cost estimate development.
  • Demonstrated ability to inspire effective teamwork and motivate staff within a matrix system.
  • Demonstrated ability to lead by example and to encourage team members to seek solutions independently.
  • Excellent communication, planning and organizational skills.
  • Ability to negotiate and liaise with clients in a professional manner.
  • Demonstrated Regulatory, GMP or QA experience.Shreeya Patel - Regulatory Affairs Recruitment Consultant at CK Clinical

 How to apply

 Apply online now 

For more information or to apply for this role, please contact Shreeya Patel on 01438 743047 or email spatel@ckclinical.co.uk Please quote reference CL25687 in all correspondence.

Are you looking for a similar position?

Click to view our current here job list

    

zp8497586rq
zp8497586rq

Our Latest Pharmaceutical Jobs – 24th of September 2012

Monday, September 24th, 2012

Looking for a job in the Pharmaceutical Industry? Please click on the links below to find out about our latest pharmaceutical jobs new in this week:

cheap cialis online

dding-top: 25px;”>RegulatorCK Clinical Recruitment UK and Europey Affairs:

RA Cross Regional Excellence Lead

Hub Labelling Manager

Regulatory Operations Specialist

Regulatory Affairs Project Manager

Drug Safety:

Pharmacovigilance Medical Writer

Senior Medical Information Scientist (contract)

Global Pharmacovigilance Regional Head

Medical Information Associate

Clinical:

Senior Biosamples Operations Manager

Biometrics:

Senior Business Analyst

Senior Clinical Operations Manager

 

Register your CV with CK Clinical

Not quite what you’re looking for? Click here to register your CV with CK Clinical today.

Once registered, one of our specialist Pharmaceutical Recruitment Consultants will be in contact to discuss your requirements and any relevant pharmaceutical jobs we are recruiting for at the moment. Good luck with your job hunt

Roche leads healthcare sector in key sustainability index for a fourth year

Monday, September 17th, 2012

WorldPharmaNews has reported that Roche has been recognised as the most sustainable healthcare company globally in the Dow Jones Sustainability Index for the fourth year in a row

The Dow Jones Sustainability Index World is the most widely accepted global assessment of how companies approach their social, economic and environmental responsibility. It monitors the performance of the leading sustainability companies based on a best-in-class approach in environmental, social and economic performance.

Severin Schwan, CEO of Roche said “Roche’s ranking as the most sustainable healthcare builds on the continued efforts do business in a way that benefits all our stakeholders. Roche is committed to engaging with communities, patients and public health in a way that creates long-term value for everyone”

 

Are you looking for a new position in the pharmaceutical industry?

Click here to search our pharmaceutical jobs online now.

GSK and University of Cambridge collaborate to develop new treatments for liver disease

Monday, September 10th, 2012

News MedicalPerfect Uninstaller – #1 Converting Uninstaller

strong> has reported that a new collaboration between the University of Cambridge and GSK will aim to discover and develop new medicines to treat liver disease.

The collaboration with GSK will combine Professor Lomas’ long-term research at the University of Cambridge Institute for Medical Research (CIMR) with GSK’s expertise in drug discovery and development in order to develop new therapeutics. Work on the project will be carried out both at GSK and at the CIMR.

This new partnership will build upon the work of researchers who have identified a molecular mechanism that plays a major role in the life-threatening liver disease that develops in patients with a particular mutant gene.

Alpha-1 antitrypsin (A1AT) deficiency is one of the most common genetic disorders in the UK, affecting approximately one in 2,000 people. Professor Lomas said that “Currently, the only option for patients with liver disease as a result of alpha-1 antitrypsin deficiency is transplantation…….This partnership brings together our collective expertise in target biology and drug discovery to tackle an unmet medical need and by teaming up with GSK, we have a great opportunity to turn our research into effective treatments”

 

Are you looking for a new position in the pharmaceutical industry?

Click here to search our pharmaceutical jobs online now.

Icon Plc forms a partnership with the University College Dublin

Thursday, September 6th, 2012

Pharmatimes cheapest viagra

g>have reported that Icon plc have joined a strategic alliance with the University College Dublin to advance research

Icon have said that this new partnership supports a shared vision for transforming research, teaching, training and innovation in the sciences in Ireland and aims to strengthen the ties between academic research and industry.

Icon have established the ICON Newman Fellowship in Genomics as one component of the partnership. This will be a two-year post-doctoral fellowship based at the UCD School of Medicine and Medical Science and at the College’s Complex and Adaptive Systems

Also ICON and the University College Dublin will work collaboratively on ways to enhance drug development.

The partners said that “This programme has “the potential to include tailored teaching programmes and internships in clinical research that will be available in Ireland and internationally through some of UCD’s university partners”,

 

Are you looking for a new position in the pharmaceutical industry?

Click here to search our pharmaceutical jobs online now.

Boehringers new lung drug promises success for COPD

Tuesday, September 4th, 2012

Pharmatimes has

reported that Boehringer Ingelheim’s new lung drug tiotropium in the Phase III data trial significantly reduced exacerbations and improved both lung function and quality of life.

The results of the trial showed that the drug could cut the risk of severe asthma exacerbation by 21% in patients who remain symptomatic despite receiving treatment for the disease.

Sttudy author Professor Huib Kerstjens of the University Medical Centre, Groningen said “While we were anticipating improvements in lung function when adding tiotropium to usual care, the significant reduction in the risk of exacerbations came as a surprise – especially given that all patients were already receiving optimal maintenance treatment as defined by the GINA guidelines”

Are you looking for a new position in the pharmaceutical industry?

Click here to search our pharmaceutical jobs online now.

Ironwood’s super drug for IBS sufferers receives FDA approval

Monday, September 3rd, 2012

Fierce Pharmaorder cialis

a> have reported that Ironwood Pharmaceuticals Inc. and Forest Laboratories Inc. won regulatory approval of their Linaclotide treatment for irritable bowel syndrome with constipation.

Linaclotide has shown in studies to help alleviate abdominal pain and symptoms of constipation. Ironwood has said that as many as 11 million Americans have irritable bowel syndrome with constipation, and for many it comes with a lot of pain. While Takeda Pharmaceutical is already in the market with its Amitiza, analysts say the fact that the Ironwood drug may relieve pain will help it quickly outsell its competition.

Linaclotide was developed by Ironwood with New York-based Forest Labs, and the companies will co-promote the drug in the U.S. Ironwood licensed the drug in Europe to Barcelona, Spain- based Almirall SA (ALM), and to Tokyo-based Astellas Pharma Inc. (4503) for several Asian countries.

Looking for a new job in the pharmaceutical sector? Start by clicking here

Pfizer and AstraZeneca enter into agreement for over-the-counter Nexium

Thursday, August 16th, 2012

As reported by WorldPharmaNews,  Pfizer and AstraZeneca have announced that they have entered into an agreement for the over-the-counter rights for NEXIUM (esomeprazole magnesium)

NEXIUM is a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease.

In the agreement to make it over the counter, Pfizer will acquire the exclusive global rights to market NEXIUM for the approved over-the-counter indications in the United States, Europe and the rest of the world.

Pfizer will make an upfront payment of $250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone and royalty payments based on product launches and sales.

Tony Zook Executive Vice President of AstraZeneca’s Global Commercial Organisation said, ” AstraZeneca has long been a leader in the gastrointestinal sector, and we believe that an OTC version of NEXIUM will complement this globally successful prescription medicine and help bring relief to more patients around the world”

 

Are you looking for a new role in the pharmaceutical industry?

Click here to see our latest pharmaceutical roles

Roche study shows that cancer drug Avastin slows brain cancer growth

Monday, August 13th, 2012

As reported by Reuters, Swiss drug maker Roche have said a new study of cancer drug Avastin showed it significantly extended progression-free survival of people with an aggressive form of brain cancer.

The Phase III AVAglio study met one of its main targets of improving progression-free survival in people with glioblastoma (a very aggressive cancer)

This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy,” Roche said.

The study’s other main endpoint is the expected time of overall survival, the results of this expected in 2013

 

Are you looking for a new pharmaceutical job in Switzerland or Europe?

Click here to see our latest jobs on Switzerland

Click here to see our latest jobs on Europe

Aleve

Search for a job

Advanced search

Search Eu

Recruiting different levels of statistical programmers

Subscribe to our newsletter

Preview
Powered by FeedBlitz


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

How this site uses cookies
Cookies are small text files that can be used by websites to make a user's experience more efficient. This site does use some non-essential cookies so we are legally obliged to inform visitors of their existence. These cookies do not track individual users or identify them, but are used to gain useful knowledge about how the site is used so that we can keep improving it for our users.

This site uses different types of cookie. We use Google Analytics, a popular web analytics service provided by Google, Inc. Google Analytics uses cookies to help us to analyse how users use the site. It counts the number of visitors and tells us things about their behaviour overall – such as the typical length of stay on the site or the average number of pages a user views.

The information generated by the cookie about your use of our website (including your IP address) will be transmitted to and stored by Google on servers in the United States. Google will use this information for the purpose of evaluating your use of our website, compiling reports on website activity and providing other services relating to website activity and internet usage. Google may also transfer this information to third parties where required to do so by law, or where such third parties process the information on Google's behalf. Google undertakes not to associate your IP address with any other data held by Google.

If you want to delete any cookies that are already on your computer, please refer to the instructions for your file management software to locate the file or directory that stores cookies. You can access them through some types of browser. More information about cookies, including how to block them or delete them, can be found on the ICO website.

Some third party cookies are set by services that appear on our pages. They are set by the operators of that service and are not in our control. They are set by Twitter, Facebook and Sharethis and relate to the ability of users to share content on this site.

If you have any queries about the use of cookies on this website please contact information@ckscience.co.uk

Close